Synopsis: With ace investor Rekha Jhunjhunwala holding about a 3 percent stake, this specialty chemical stock rose 7 percent as its $300 million agrochemical CDMO project begins commercial dispatches in March, unlocking fresh revenue visibility.
A small-cap specialty chemical company surged around 7 percent after announcing that commercial dispatches from its $300 million agrochemical CDMO project will begin in mid-to-late March 2026. The project is expected to start generating revenue from this quarter itself and could contribute hundreds of crores annually over time, strengthening its position as a manufacturing partner for global agrochemical innovators.
With a market cap of more than Rs 9,100 Cr, Jubilant Ingrevia Ltd saw its stock hit an intraday high of Rs 577 which is 7 percent higher than the previous close of Rs 541. The company stock has given a compounded return of 7 percent in the last three years.
Why the surge?
Jubilant Ingrevia is set to achieve a major strategic milestone in mid-to-late March 2026 by commencing commercial dispatches for its $300 million agrochemical CDMO contract. This project’s operational startup marks a pivotal moment, as it transitions the company’s significant infrastructure investment into an active, revenue-generating phase within the current quarter.
This development strengthens the company’s position as a key manufacturing partner for global agrochemical innovators. By leveraging a partner’s proprietary technology, this contract is expected to drive long-term value. With revenue visibility beginning this month, the launch underscores the company’s successful scale-up of its high-margin Custom Development and Manufacturing Organization business.
Quarterly Capex
In Q3 FY26, the company boosted operational efficiency by commissioning a new boiler at our Bharuch site. Construction also began on a new multipurpose plant in Gajraula, significantly expanding capacity and flexibility for its CDMO and Fine Chemicals portfolios. These strategic initiatives keep us confident in sustaining our growth trajectory.
Ace Investor Holding
As of Q3FY26, Rekha Jhunjhunwala holds about 3 percent stake in the company. According to the available sources, the ace investor has held around the same percent of stake since Q4FY21.
Business & Financial Overview
Jubilant Ingrevia is a global, integrated life sciences and specialty chemicals company. It operates across three main segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. Serving pharmaceutical, agrochemical, and nutrition industries, the company provides high-quality, customized products and offers contract development and manufacturing (CDMO) services globally.
In the latest quarter, the company saw a YoY revenue decline of 1 percent, going from Rs 1057 Cr in Q3FY25 to Rs 1051 Cr in Q3FY26, while the QoQ revenue has fallen by 6 percent from Rs 1121 Cr in Q2FY26. The YoY Net Profits have fallen by 32 percent, going from Rs 69 Cr in Q3FY25 to Rs 47 Cr in Q3FY26, while the QoQ profits have also fallen by 32 percent from Rs 69 Cr in Q2FY26.
The company has a 3 year sales CAGR of negative 5 percent, while the TTM is at 1 percent. The company’s 3 year profit CAGR is at a negative 20 percent, while the TTM number is at 33 percent. The company also has a ROCE of 11 percent and a ROE of 9 percent.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Chemical Stock in Focus After $300M Agrochemical CDMO Project Set to Start Commercial Production appeared first on Trade Brains.